News
To keep up-to-date with the latest in regulatory science, follow CIRS on LinkedIn and sign up to the CIRS mailing list.
For CIRS publications including R&D Briefings, journal articles and reports, please visit the Publications area.
July Newsletter
Take a look at our latest newsletter, which shares updates on key research activities and publications in the second quarter of 2025. Download newsletter
Q1 2025 Newsletter
Take a look at our latest newsletter, which shares updates on key research activities and publications in the first quarter of 2025. Download newsletter
2025 CIRS Research Agenda
We're pleased to announce that CIRS has published a new Research Agenda, which can be downloaded here. This brochure outlines our research priorities for 2024-2026 as well as plans [...]
Latest CIRS activities on rare diseases
In recognition of Rare Disease Day today, we wanted to share what CIRS has been up to recently to help advance regulatory and HTA policies and processes in the [...]
CIRS participates in new RDI-Lancet Commission on Rare Diseases
CIRS is participating in the Rare Diseases International-Lancet Commission on Rare Diseases (RDI-LCRD), which aims to catalyse global recognition and action for people living with a rare disease, driving systemic change to [...]
Webinar on Public Assessment Reports (PARs)
If you missed it, you can watch the full webinar here, available in Spanish, English and Portuguese. Join us for a webinar on public assessment reports (PARs) on [...]
Winter 2024 Newsletter
Before everyone signs off for the festive season, we’d like to share a few things that CIRS has been up to recently, as well as a summary of our [...]
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and between regulatory and HTA agencies at national and regional levels. This blog by Martina [...]
Strategies for regulatory alignment in East Africa
As part of the Optimising Efficiencies in Regulatory Agencies (OpERA) programme, CIRS has been working closely with regulatory agencies in the East African Community Medicines Regulatory Harmonisation (EAC-MRH) initiative to evaluate [...]
Regulatory processes for rare disease drugs in the US and EU: National Academies study supported by CIRS
A new report from the NASEM Health and Medicine Division offers recommendations for enhancing rare disease drug development. CIRS is delighted to have been able to collaborate with NASEM [...]